 A Phase II study to investigate the potential utility of PD 0332991 in the treatment of early stage ER Human epidermal growth factor receptor 2 HER2- breast cancer, to investigate whether the combination of PD 0332991 and anastrozole is able to: 1 improve the pathologic complete response rate when compared to the historical control of single agent aromatase inhibitors, 2 result in fewer patients with on therapy Ki6710 compared to historical control. 